448 results about "Serine" patented technology

The invention belongs to the technical field of biology, and particularly relates to application of serine in relieving heat stress of pleurotus ostreatus and a method. Under the heat stress condition, exogenous serine supply promotes pleurotus ostreatus hypha to recover growth, and the activity of antioxidant enzyme, the yield of sporocarp and the yield of nutrient substances are improved; when the activity of the PHGDH enzyme is inhibited, the serine synthesis is reduced; the hypha growth can be promoted by overexpressing the phgdh, and the enzymatic activity of the PHGDH can be improved; when acetyltransferases HAT, NAT1, NAT2 and NAT3 act on a K394 site of the PHGDH, the enzyme activity of the PHGDH can be improved, endogenous serine metabolism is activated to respond to heat stress, it is indicated that PHGDH-mediated serine metabolism plays an important role in corresponding heat stress of the pleurotus ostreatus, and the invention discloses a mechanism for improving heat resistance of the pleurotus ostreatus through the PHGDH-mediated serine metabolism. And a foundation can be laid for breeding high-temperature-resistant pleurotus ostreatus dominant strains.

The invention relates to the technical field of related drugs for nerve injury caused by heavy metal pollution, in particular to application of a compound for inhibiting phosphorylation of ARMC10 in preparation of drugs for antagonizing tin-induced nervous system injury. Exposure of trimethyltin chloride induces nerve cell mitochondrial dysfunction, and the key mechanism is ARMC10 serine 43 site abnormal phosphorylation. Phosphorylated protein causes excessive mitochondrial fission, membrane potential collapse and energy metabolism disorder, resulting in neuron damage. Based on the target spot, a compound for antagonizing tin-induced nervous system injury is obtained through screening, protein phosphorylation can be specifically inhibited, mitochondrial dynamic unbalance and dysfunction induced by trimethyltin chloride are effectively reversed, and neurotoxicity is relieved. According to the technical scheme, the technical problem that in the prior art, no medicine for effectively antagonizing tin-induced nervous system injury exists can be solved, and the compound has the application potential for treating the nervous system injury and cognitive impairment caused by tin exposure.

The invention relates to the technical field of functional food and biological medicine, in particular to a modified pseudo-ginseng exosome and an intestinal conditioning gel composition and application thereof. According to the gel beverage, an exosome derived from panax notoginseng callus cultured in a laboratory is used as a core active component, is modified through phosphatidylserine-aminated pectin-genipin and is embedded into a hydrogel matrix composed of carboxymethyl chitosan and sodium alginate, so that the exosome is protected from being degraded in the stomach, and the activity of the exosome in the stomach is improved. The exosome can be effectively released under the intestinal pH and flora environment, so that the targeted delivery of the intestinal tract is realized, and the preparation method is suitable for improving the intestinal inflammation and maintaining the intestinal health. The invention can effectively solve the technical problems of uncontrollable raw material quality and safety, low oral delivery stability and active ingredient availability and poor medication compliance of the existing plant exosome.

Among other things, provided herein are systems that replace the natural random integration activity of a retrovirus with site-specific integration machinery. This approach allows for a more precise targeting of a gene of interest into a human genome, e.g., for therapeutic purposes. The system may include integration-deficient retrovirus (e.g., lentivirus) (IDLV), in which the natural integration activity has been reduced (e.g., by mutation to the viral integrase polypeptide). Instead, the system may comprise a site-specific recombinase (e.g., a serine recombinase, e.g., a serine integrase) capable of directing insertion of a template DNA, or portion thereof, into a desired site in the human genome.

The invention discloses an amino acid composition for treating alopecia and application of the amino acid composition in preparation of a medicine for treating alopecia, and belongs to the field of medicine configuration products, the amino acid composition is composed of a targeting core intervention component and an auxiliary strengthening synergistic component, the targeting core intervention component is prepared from 30-50 parts of arginine, 50-155 parts of lysine and 50-120 parts of glutamic acid, and the auxiliary strengthening synergistic component is prepared from an auxiliary strengthening synergistic component and an auxiliary strengthening synergistic component. 10 to 40 parts of cysteine and 20 to 60 parts of leucine; the auxiliary strengthening synergistic component is prepared from 15 to 45 parts of tyrosine, 15 to 40 parts of glycine, 10 to 40 parts of glutamine, 20 to 35 parts of serine, 5 to 25 parts of alanine, 2 to 20 parts of aspartic acid and 15 to 35 parts of phenylalanine; the composition can be used as an active ingredient to be prepared into different dosage forms such as a pigmentum, a spray, an ointment and a liniment, is applied to prevention of alopecia and promotion of hair growth, and has a remarkable treatment effect.

The invention discloses a serine hydroxymethyltransferase mutant and an application thereof in production of L-serin.The serine hydroxymethyltransferase mutant with the specific enzyme activity remarkably improved is obtained by conducting saturated mutation on serine hydroxymethyltransferase from escherichia coli and conducting screening, and the serine hydroxymethyltransferase mutant is applied to synthesis of L-serine. The serine hydroxymethyltransferase disclosed by the invention can be used for effectively improving the efficiency of catalyzing glycine and formaldehyde to synthesize L-serine by using the serine hydroxymethyltransferase, reducing the enzyme dosage, remarkably reducing the production cost and reducing the separation difficulty of downstream products.

The invention discloses a preparation method of a nano-liposome coated NAD amino acid nutrient solution, and relates to the technical field of liposome amino acid nutrient solution preparation, the preparation method comprises the following steps: S1, preparing raw materials: S1.1, preparing NAD amino acid; s1.2, lecithin: using pure natural lecithin from soybeans and eggs; s1.3, preparing sodium hyaluronate: adopting sodium hyaluronate with low molecular weight; s1.4, preparing an amino acid compound, wherein the amino acid compound contains a plurality of essential amino acids, including glycine, serine and lysine; according to the mask, when the NAD amino acid nutrient solution wrapped by the nano-liposome is applied to the mask, the mask can more effectively permeate into the deep layer of the skin due to the excellent stability and biological activity of the NAD amino acid nutrient solution, and sufficient nutrition and moisture are provided for the skin; meanwhile, due to the strong anti-aging effect, the mask can remarkably improve the skin texture, reduce fine wrinkles and wrinkles, and make the skin more compact, smoother and elastic.

The invention belongs to the technical field of biology, and discloses a transaminase GabT1 mutant S106I, a construction method thereof and application of the transaminase GabT1 mutant S106I in biosynthesis of 1-deoxynojirimycin. According to the invention, the 106th serine near the molecular catalytic domain of the transaminase GabT1 derived from bacillus amyloliquefaciens is mutated into isoleucine in a site-directed mutagenesis manner, so that the catalytic efficiency of the transaminase GabT1 is remarkably improved, the problem that the catalytic efficiency of the transaminase GabT1 on fructose-6-phosphoric acid is not high at present is solved, and the application of the transaminase GabT1 to the fructose-6-phosphoric acid is promoted. The yield of 1-deoxynojirimycin synthesized by the mutant GabTS106I is increased by 43.87% compared with that of a wild type. The 1-deoxynojirimycin fermentation production capability of the transaminase GabT1 mutant and the engineering strain obtained by the invention is greatly improved, and the transaminase GabT1 mutant and the engineering strain have a good industrial application prospect.

A CVB virus expression vector comprising a PIV5 W3A viral genome comprising a mutation at amino acid residue S157 or S156 of the P / V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) with phenylalanine (F) or asparagine (N), and the SH gene has a deletion of the SH open reading frame or the entire SH gene transcription unit. The CVB virus expression vector expresses a heterologous polypeptide, including SARS-CoV-2 spike (S), and / or nucleocapsid (N) and / or membrane (M) proteins, RSV fusion protein (F), or other antigens.

The present invention relates to nuclear mitotic apparatus (NuMA) protein serine 395 (S395) phosphorylation inhibitor for use in preventing and / or treating cancer in a subject. The invention also relates to a pharmaceutical composition comprising a NuMA S395 phosphorylation inhibitor. Furthermore, the invention provides a method of screening for a candidate compound for preventing and / or treating cancer, and a method of detecting a dormant cancer cell in a subject. Corresponding methods of treating and / or preventing cancer are also provided.

The invention provides a single-chain and double-protein-expressed circular RNA construct and a preparation method and application thereof, and the single-chain and double-protein-expressed circular RNA construct comprises 5'and 3 'introns used for realizing RNA self-splicing and cyclization as a first kind of introns; the 5'and 3 'homologous arms are used as pairing sites in RNA molecules; the exon 1 and the exon 2, which are connected after being spliced, can be spliced and connected together under the action of the first type of introns to form a complete and continuous open reading frame; an interval sequence for providing spatial and adjustment sequence structures; the IRES is used for starting translation; a glycine-serine linker as a flexible linker; a green fluorescent protein for gene expression monitoring; a luciferase for producing light by a catalytic chemical reaction. All the advantages of the double-IRES system for generating natural complete protein are reserved, and the core defect of low efficiency can be thoroughly overcome.

Disclosed herein are engineered LSR sequences, compositions, and uses including in genome-editing systems and therapeutic compositions. The LSRs can facilitate nucleic acid recombination at particular attachment sites, using suitable donor sequences. The disclosed LSRs may be used to site-specifically recombine or integrate nucleic acid sequences for a variety of purposes, including treatment of human diseases.

The invention belongs to the technical field of organic synthesis, and particularly relates to a preparation method of a hydrogenated lecithin acyl serine intermediate. By selecting the specific deprotection agent, the generation of isomers can be effectively reduced, so that the high-purity hydrogenated lecithin acyl serine intermediate is obtained, and the method has the characteristics of simple post-treatment, low cost, environmental friendliness and the like.

The present disclosure relates to compositions comprising lipid nanoparticles (LNPs) configured for targeting dendritic cells. In particular, the present disclosure provides LNPs comprising a serine-based helper-lipid, a PEG lipid, an ionizable lipid, a cholesterol component, and one or more nucleic acids. The present disclosure provides use of the LNPs for the delivery of nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in various therapeutics, such as for the treatment of cancer or autoimmune diseases or prevention of infectious diseases. Finally, methods are provided for preparing such LNPs.

The application provides a polypeptide, a plant immune elicitor and application thereof. The polypeptide has 10 or 11 amino acid residues; the amino acid at the first position of the polypeptide is serine, and the amino acids at the 9th and 10th positions are both cysteine; if the polypeptide has 11 amino acid residues, the amino acid at the 11th position of the polypeptide is asparagine. The polypeptide can solve the problem that there is no small peptide secreted by gramineae plants in the prior art, and is suitable for the field of plant immune elicitors.

A provided self-replicating mRNA is transcribed from an alphavirus backbone vector. The alphavirus backbone vector comprises gene sequences of alphavirus non-structural proteins nsP2, nsP3, nsP4, and mutated nsP1. A cysteine at position 492 of the mutated nsP1 is mutated into serine. The self-replicating mRNA has a higher expression level and a longer expression time for a target gene. The self-replicating mRNA is used for expressing IMP3, and can be prepared into a vaccine having good preventive and therapeutic effects on IMP3-positive tumors. Therefore, the present invention has good application prospects in drug and vaccine development.

The present disclosure describes PLPC-DB, an ultrapure phospholipoproteomic composition consisting of essential phospholipids, bioactive proteins, and intercellular regulatory factors, derived from the supernatant of peripheral blood mononuclear cells (PBMCs). This composition achieves a purity level exceeding 99% through a patented purification process that integrates high-speed advanced centrifugation and selective ultrafiltration, ensuring the structural stability and functional integrity of its bioactive components. PLPC-DB is optimized for advanced research and diagnostic applications, providing reproducibility, consistency, and safety across multicenter studies. The essential biomolecular components of PLPC-DB include phosphatidylcholine and phosphatidylserine, which contribute to membrane stability and intracellular signaling, while cell communication peptides enhance intercellular signaling, homeostatic regulation, and biochemical coordination. Structural and regulatory lipids support cell membrane biogenesis and functional stability, whereas adhesion and signaling proteins mediate cell-cell interactions and immune response coordination. Additionally, bioactive regulatory factors modulate immune and inflammatory responses, contributing to tissue regeneration and metabolic homeostasis.

This invention discloses an acidic serine keratinase gene and its applications, belonging to the field of genetic engineering technology. This invention screened a novel serine keratinase from the acidic hot spring environment of Niujie, Yunnan. This keratinase naturally possesses characteristics of acid resistance, good thermal stability, and high enzyme activity, allowing it to adapt well to the acidic microenvironment of the skin and temperature fluctuations throughout the product's production, storage, and transportation processes. Furthermore, it eliminates the need for complex stabilization treatments, simplifying the production process, reducing production costs, and extending the product's shelf life. This achieves green and efficient preparation, fundamentally solving key problems of existing keratinases in skin applications, such as irritation, poor stability, and difficulty in storage. It is particularly suitable for the gentle exfoliation of human keratin plugs, demonstrating outstanding application value and broad prospects in the daily chemical skincare field.

The application discloses a method for preparing rice with changed tiller number, and belongs to the technical field of genetic breeding. The method comprises the following steps: introducing a coding gene of an OsD14 mutant into target rice to obtain rice with changed tiller number, wherein the tiller number of the rice with changed tiller number is higher or lower than that of the target rice, and the OsD14 mutant is a protein obtained by mutating the 10th, 11th, 13th and 15th amino acids in SEQ ID NO: 1 into other amino acids and keeping other amino acids in SEQ ID NO: 1 unchanged. It is proved by experiments that whether ubiquitination degradation of the OsD14 occurs is related to a phosphorylation state of the OsD14, the number of rice tillers is adjusted by using the phosphorylation state of the OsD14, and the plant type is improved, so that the yield of the rice is improved, and the method has a wide application prospect.

A reagent for measuring activated partial thromboplastin time, the reagent comprising phosphatidylcholine (PC), phosphatidylserine (PS), and phosphatidylethanolamine (PE), wherein the ratio (PS / PC) of the concentration of the PS to the concentration of the PC is 0.26-2.00, and the concentration of the PS is 14-60 µg / mL.

The present disclosure provides a method for producing a methyl compound using glycine, serine, or an organic raw material.

The invention discloses a multifunctional special dietary food skin beautifying and shaping formula and application, and belongs to the technical field of beauty treatment. The multifunctional special dietary food at least comprises collagen peptide, collagen tripeptide, skipjack elastin peptide, carob bean extract, phosphatidylserine, casein hydrolytic peptide, nicotinamide, rice bran oil powder, haematococcus pluvialis, cranberry powder, oriental cherry flower powder, pig blood peptide powder, red date peptide powder and cattle spleen peptide. The health-care product can comprehensively supplement nutrition recovered after exercise, has the effects of beautifying, shaping and removing wrinkles, can effectively relieve pressure and regulate emotion, and also has the effects of improving female physiological health, strengthening the spleen and stomach and enhancing immunity.

The invention relates to the technical field of biological medicine, and particularly discloses a macrophage membrane coated plateau encephaledema drug carrier and a preparation method and application thereof, and the macrophage membrane coated plateau encephaledema drug carrier is composed of a nanoparticle core and a macrophage membrane shell layer wrapping the core; the nanoparticle core comprises an ROS-responsive carrier material and carbon monoxide release molecules MnCO entrapped in the ROS-responsive carrier material; the content of phosphatidylserine in the shell layer of the macrophage membrane is not less than 5 mol% of the total phospholipid of the membrane. According to the invention, a bionic delivery system of ROS response type MnCO nanoparticles coated with a macrophage membrane is constructed, phosphatidylserine on the surface of the membrane is utilized to actively activate a microglial cell Trem2 receptor, a positive feedback cycle of targeting phagocytosis-CO release-Trem2 up-regulation is formed, and at the same time, fatty acid oxidative metabolism reprogramming is promoted by means of degraded membrane lipid, so that the biomimetic delivery system is used for preparing the ROS response type MnCO nanoparticles. And multi-mechanism synergistic efficient brain-targeted therapy is realized.

To provide an antigen-binding protein comprising an antigen-binding domain that binds to plasmin. Also provided are compositions comprising the antigen binding proteins, as well as uses thereof and methods of treatment comprising the same.SOLUTION: To provide antigen-binding proteins or antigen-binding fragments thereof that specifically bind to the serine protease domain of plasmin and inhibit or reduce plasmin activity via interaction with the catalytic site of the protein.SELECTED DRAWING: None

According to the scheme, the recombinant macrolide enzyme and the preparation method and application thereof are provided, the amino acid sequence of the recombinant macrolide enzyme is shown as SEQ ID NO.1, and the recombinant macrolide enzyme is obtained by site-directed mutagenesis of an erythromycin esterase family protein sequence derived from enterobacter hormaechei; the mutation sites are as follows: the 44 glutamic acid is mutated into asparagine, the 55 tyrosine is mutated into proline, the 153 proline is mutated into alanine, and the 219 serine is mutated into glutamic acid, so that the specific macrolide lactonase which is efficient, stable, easy to prepare on a large scale and more suitable for environmental requirements is prepared, and macrolide antibiotic pollution is removed; and the method has good economic benefits and practical values.

This invention discloses a highly efficient serine protease for degrading α-keratin, its degradation method, and its applications. The serine protease is named PliKerS, and its full-length amino acid sequence is shown in SEQ ID No. 2, with the corresponding coding gene sequence shown in SEQ ID No. 1. The amino acid sequence of the recombinant serine protease rPliKerS, which has its N-terminal signal peptide removed and a purification tag attached to its C-terminus, is shown in SEQ ID No. 4, with the corresponding coding gene sequence shown in SEQ ID No. 3. The recombinant serine protease rPliKerS degrades α-keratin under mild conditions, avoiding the environmental burden of strong alkaline treatment. It is particularly suitable for applications involving pet hair, hair waste, and leather pretreatment. The degradation products are soluble proteins and peptides, which can be used as high-value-added amino acid raw materials, functional peptide raw materials, biodegradable materials, bio-based material precursors, bio-feed proteins, fertilizers, etc., exhibiting high resource utilization value and promising industrial application prospects.

The present invention relates to an engineered strain for producing L-serine, a construction method therefor and the use thereof. The expression levels of SerA, SerB and SerC are modified and regulated on the genome of a starting strain to coordinate the metabolic flux, thereby facilitating the synthesis and production of L-serine. Specifically, different expression elements are used to regulate the expression levels of SerA, SerB and SerC to reach an optimal ratio range, so that the expression level of serC is 3-7 times that of serA and serB. The expression levels are transcriptional and / or translational levels of the genes. The obtained L-serine high-yield engineered strain achieves an L-serine yield of 23.2 g / L, with a conversion rate of 22%.

A composition for promoting tyrosinase activity, which includes a peptide consisting of the amino acid sequence of General Formula 1 below: K—Y—R1-R2-R3-R4-R5-R6-R7-R8 (General Formula 1) is disclosed. In General Formula 1, R1 is arginine (R), lysine (K), or glutamine (Q); R2 is arginine (R) or glutamine (Q); R3, R4, and R5 are each arginine (R) or lysine (K); R6 is asparagine (N) or serine (S); and R7 and R8 are each lysine (K) or tyrosine (Y). The composition may promote melanogenesis in melanocytes to prevent, improve or treat hypomelanosis.

The invention provides novel compounds of formula (I), stereoisomers and pharmaceutically acceptable salts thereof: (wherein: Q is a lipophilic, zinc chelating moiety which is selective for Zn2+ ions; L1 is a covalent bond or a C1-6 alkylene chain in which one or more -CH2- groups of the alkylene chain are optionally replaced by a group independently selected from -CO- and -NR4- (where R4 is H or C1-3 alkyl); Y is selected from the following groups: (II) and (III) (where each R5 is independently H or C1-3 alkyl; and R6 is H or C1-3 alkyl); L2 is a covalent bond or a C1-6 alkylene chain in which one or more -CH2- groups of the alkylene chain are optionally replaced by a group independently selected from -CO- and -NR7- (where R7 is H or C1-3 alkyl); R is -OH, -O-C1-6 alkyl, -O-(CH2)p-O-CO-C1-6 alkyl (where p is an integer of 1 or 2) or -O-CH(CH3)-O- CO-C1-6 alkyl; each R1 is independently selected from halogen and C1-3 alkyl; each R2 is independently selected from halogen and C1-3 alkyl; R3 is H or C1-3 alkyl; n is an integer of 0 or 1; and m is an integer of 0 or 1). The compounds according to the invention are selective zinc chelators that find use as adjuvants in the treatment of bacterial infections and / or bacterial biofilms that harbour such infections. For use in such treatment, the compounds are used in combination with an antibacterial agent, for example a β-lactam antibiotic. The invention further provides a triple combination therapy for use in the treatment of bacterial infections and / or bacterial biofilms which comprises co-administration of the compounds to a subject in combination with a β-lactam antibiotic and a serine β-lactamase inhibitor.

This invention provides a compound drug for treating melioidosis, its preparation method, and its application. The drug comprises active components of traditional Chinese medicine, a bioactive preparation, and a pharmaceutically acceptable carrier. The active components of traditional Chinese medicine are primarily extracts of Scutellaria baicalensis, Coptis chinensis, Fagopyrum dibotrys, and Polygonum cuspidatum. The bioactive preparation includes polymyxin B, homoserine lactonease, and recombinant human β-defensin 3. The components work synergistically to construct a comprehensive intervention system covering all pathological stages, including biofilm disruption, sterilization, anti-endotoxin activity, intracellular bacterial clearance, immune regulation, and tissue repair. This system can effectively disrupt bacterial biofilms, kill multidrug-resistant strains, neutralize endotoxins, and eliminate latent intracellular bacteria, addressing the core pain points of existing melioidosis treatments, such as strong drug resistance, significant toxic side effects, and high recurrence rates. The preparation process of this invention is carried out under low-temperature and sterile conditions throughout, which fully preserves the stability of the active ingredients, making it suitable for industrial production. The drug can be prepared in various dosage forms, covering all clinical subtypes of melioidosis, and possesses clinical application value and promising prospects for widespread application.